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Abstract
Chemokine-dependent localization of specific B cell subsets within the immune microarchitecture 
is essential to insure successful cognate interactions. While cognate interactions between T cells 
and memory B cells (Bmem)5 are essential for the secondary humoral immune responses, the 
chemokine response patterns of Bmem cells are largely unknown. In contrast to naïve B cells, this 
study shows that antigen-specific Bmem cells have heightened expression of CCR6 and a selective 
chemotactic response to the CCR6 ligand, CCL20. While CCR6 appears be non-essential for the 
initial clonal expansion and maintenance of Bmem, CCR6 is essential for the ability of Bmem to 
respond to a recall response to their cognate antigen. This dependency was deemed intrinsic by 
studies in CCR6-deficient mice and in bone-marrow chimeric mice where CCR6 deficiency was 
limited to the B cell lineage. Finally, the mis-positioning of CCR6-deficient Bmem was revealed by 
immunohistological analysis with an altered distribution of CCR6-deficient Bmem from the 
marginal and perifollicular to the follicular/germinal center area.
5Abbreviations: Bmem, memory B cell; BM, bone marrow; PC, Plasma Cell;
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Introduction
Long-lived serological memory is the product of long-lived memory B cells (Bmem) and 
plasma cells (PC). Bmem cells are long-lived although their half-life is as-yet undefined in 
both mouse and man (1). Bmem cells are quiescent, they can be IgM memory or express 
isotype-switched and somatically hypermutated membrane immunoglobulin (2, 3). IgM 
Bmem cells are produced independent of T cell help, differentiate in the absence of GC 
structure (4), produce natural antibodies (3) and part of circulating marginal zone B cells (2). 
Upon exposure to their cognate antigen, Ig switched and IgM+ Bmem, rapidly divide to 
daughter Bmem and differentiate to PC (5). Lastly, PCs residing in the bone marrow (BM) 
are long-lived cells, quiescent, terminally-differentiated and produce Ig for long periods of 
time (6).
The appropriate anatomic localization of individual B cell subsets is essential to execute 
their specific functions, with chemokines controlling B cell localization within the immune 
microarchitecture (7). For example, CXCR5 and CCR7 orchestrate the precise localization 
of naïve B cell in secondary lymphoid organs and spleen (8–10). In addition, it has been 
demonstrated that the differential expression of CXCR4 and CXCR5 plays an important role 
in the localization of antigen-activated B cells during germinal center (GC) formation, 
permitting the selection of the most suitable clones during PC differentiation (11). Finally, 
downregulation of CXCR5 and CCR7 expression by PCs with sustained expression of 
CXCR4, mediates the migration of PCs from secondary lymphoid organs to the BM and 
sustains PC survival (12, 13).
CCR6 is expressed in different subsets of CD4 and CD8 T cells (14), immature DCs (15), 
NK T cells (16) and B cells (17, 18). Prior work demonstrated that Bmem cells also express 
CCR6, and it was proposed that CCR6 may contribute to the migration of this population to 
the mucosal tissue (19). However the role of this receptor in secondary humoral immune 
responses was not studied.
The studies presented here show that antigen-specific Bmem cells express heightened levels 
of CCR6 and display an increased chemotactic response to the CCR6 ligand, CCL20, when 
compared to naïve B cells. Neither the primary humoral response nor the initial generation 
and maintenance of antigen-specific Bmem cell are impaired in CCR6-deficient mice. 
However, genetic deletion of CCR6 in B cells prevents antigen-specific Bmem from 
mounting an effective secondary response upon antigen re-challenge and disrupts their 
normal CCL20-dependent anatomic distribution in the spleen. Together these observations 
show that CCR6 is essential for appropriate anatomical positioning of Bmem and the ability 
of Bmem to be recalled to their cognate antigen.
Material and Methods
Mice and Immunizations
These studies were approved and conducted in accredited facilities in accordance with the 
Institutional Animal Care and Use Committee (IACUC) of Dartmouth College (Lebanon, 
NH. USA) and UK Animals (Scientific Procedures) Act 1986 (Home Office license number 
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PPL 70/7102). Cγ1–Cre mice were provided by K. Rajewsky (Harvard Medical School, 
Boston MA) and S. Casola (Fondazione Italiana per la Ricerca sul Cancro Institute of 
Molecular Oncology Foundation, Milan, Italy). C57/BL6 mice were purchased from the 
NCI and Charles River. CCR6−/−, Rosa YFPfl/fl and μMT mice were purchased from The 
Jackson Laboratory. All animals were maintained in a pathogen-free facility at Dartmouth 
Medical School and King’s College London. For primary immunizations, 10μg of PE 
(Chromoprobe) adsorbed to prepared alum was injected intraperitoneally (i.p.) in a volume 
of 200μl. For secondary challenge, 10μg of PE in PBS in a volume of 200μl was injected i.p.
Cell Preparation
To sort memory B cells, single cell suspensions of lymphocytes were prepared as previously 
described (1). Splenocytes were incubated with anti-IgD-biotin, anti-IgM-biotin, anti-CD8α-
biotin and anti-CD4-biotin, with these cells removed using the EasySep biotin Selection kit 
for mouse cells (Stem Cell Technologies).
Flow Cytometry
Antibodies against the following antigens were used: B220 (clone 6B2), IgG1 (clone 
A85-1), IgD clone (11–26c), IgM (clone II/41), CD4 (clone GK1.5), CD8 (clone 2.43), 
CD38 (clone 90), CD23 (clone B3B4) and CCR6 (clone 29-2L17), Sign-R1 (clone ERTR9). 
PE-binding cells were detected by staining with 1μg/ml PE. Samples were acquired with a 
refurbished Becton Dickinson FACSCAN running CellQuest software (BD Bioscience) and 
data were analyzed by FlowJo (Tree Star) software. Cell sorts were performed on a BD 
FACSAria with 10,000– 100,000 cells sorted and postsort analysis indicating purities 
exceeding 98% (Flow Cytometry Facility at Dartmouth Medical School).
Real Time PCR
Total RNA was isolated from either purified memory or naïve B cells using TRIzol 
(Invitrogen) followed by secondary purification over RNeasy columns (QIAGEN) with a 
DNase-I treatment step. 1 μg of DNA-free RNA was reverse transcribed to cDNA using 
Omniscript RT (QIAGEN). Real-time PCR was performed with the SYBR Green PCR Core 
Kit (Applied Bio- systems) on an iCycler iQ instrument (Bio-Rad Laboratories). 
Amplification conditions were 95°C for 8 min, followed by 40 cycles of 94°C for 15 s, 62°C 
for 45 s, and 72°C for 15 s. Primers for the control gene mouse β-actin were as follows: 
forward, 5′-CCAATGTGTCCATGTCATTT-3′ and reverse, 5′-CAATA- 
GTGATGACCTGGCCGT-3′. CCR6−/− used was as follows: forward, 5′-
CCCAGCACATCATAGCATTG-3′ and reverse, 5′-TGGGAGAGCAGAGGTGAAGT-3′. 
For CCL20 gene expression, TaqMan gene expression assays containing FAM dye-labeled 
TaqMan MGB probe was used for mouse CCL20 (Mm01268754_m1) in multiplex with 
primer-limited assays for β-actin endogenous control, containing VIC/MGB probes. Real-
time quantification was performed using Taq- Man gene expression master mix on a Bio-
Rad CFX96 optical reaction module on a C1000 thermal cycler. Data were analyzed using 
CFX Manager Software (Bio-Rad). Relative RNA expression was determined using the 
formula relative expression = 2−(ΔΔCT) × 1,000, where ΔΔCT = (cycle threshold [CT] gene 
of interest - CT β-actin in experimental sample) - (CT gene of interest - CT β-actin in a no-
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template control sample) (see the ΔΔCT method, Taqman® Bulletin 2: Applied 
Biosystems).
Chemotaxis assays
Chemotactic migration assays were performed, as previously described (15). Briefly, 
between 5 × 106 splenocytes were placed in the upper chamber of 5-μm of 24-well plates 
transwell inserts (Corning Costar, Cambridge, MA), in contact with 600 μl of medium 
(RPMI-1640 with 10% FBS) with or without chemokine. After 2 h, a fixed volume of 
counting beads (Polysciences Inc., Warrington, Pennsylvania, USA) was added to each well 
for normalization, and the specific migration of Bmem or naïve B cells was enumerated by 
flow cytometry after staining for the B lymphocyte subsets of interest. Mouse RANTES, 
CCL17, S1P, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CCL20, CCL21 and CCL22 
were purchased from Peprotech Inc.
Microscopy/Immunofluorescence
For germinal center structure analysis, tissues were snap-frozen and 8 μm sections were 
fixed with methanol prior to staining with PNA-FITC, anti mouse/human B220-A647 and 
anti mouse monoclonal antibody ERTR9-biotin plus streptoavidin-A455. Slides were 
analyzed by a confocal microscope (LSM510Meta, Zeiss).
To detect Bmem and YFP expression, tissue was removed, fixed in 4% paraformaldehyde, 
followed by overnight saturation in 10% sucrose at 4°C. Tissue was then snap frozen in 
OCT Tissue-Tek freezing medium (Sakura). Cryostat sections of 7 μm were air dried and 
washed in PBS. Blocking was performed with 20% normal horse serum (PAA Laboratories 
Inc.) for 15 minutes at room temperature. Sections were incubated with Alexa Fluor 488 -
conjugated anti-GFP (Life Technologies) and biotin-conjugated anti-mouse B220 (Clone 
RA3-6B2, Ebioscience), anti-mouse Igm/IgD (clone 11/41; 11–26c, Ebioscience), or anti-
mouse MOMA (Abcam), followed by streptavidin Alexa Fluor 594 (Life Technologies). 
Nuclei were visualised by staining with 1μg/ml DAPI (Invitrogen). Negative controls were 
Rosa YFP mice (no GFP) or stained with isotype-matched antibodies. Images were acquired 
on an Olympus BX51 microscope using Micro-Manager software (Vale Laboratory).
ELISPOT/ELISA Analysis
ELISPOTs were developed as previously described (1), single cell suspensions from bone 
marrow and spleen were counted and were apportioned to PE coated Multiscreen 96-well 
plates (Millipore) with twofold serial dilutions made before incubation for 4h at 37°C. PCs 
were detected by HRP-conjugated anti-mouse IgG1 polyclonal antibody (Southern 
Biotechnology Associates, Inc.).
For ELISA analysis, plates were coated with 10μg/ml PE overnight in PBS, blocked with 
PBS + 5% FBS, washed, and then 1:2000 diluted serum added at serial 1:2 dilutions. Serum 
from either a PE hyper-immunized mouse was included on each plate as a reference between 
plates and between experiments and used to generate a standard curve, with these serum 
allotted the value 8000 arbitrary units. Antibody levels were detected with IgG-AP 
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(Southern Biotechnology) and developed with 1mg/ml pNPP (Sigma) in 0.05mM sodium 
carbonate buffer.
Irradiation and Chimera Generation
For the generation of mixed chimera C57BL6 mice were lethally irradiated (600 rad) twice 
and reconstituted (i.v.) with a mixture of 5×106 bone marrow cells of 80% μMT origin and 
20% with wt or CCR6KO cells. Successful grafting was determined by flow cytometry of 
peripheral blood 8 weeks after transplantation. Immunizations and re-challenge responses 
were performed 8 weeks and 2 month after bone marrow transplant respectively.
Statistics
Results are expressed as mean plus or minus SEM. Two-tailed Student t test with unequal 
variance was used to evaluate the statistical significance of the data.
Results
Increased expression of CCR6 and enhanced chemotaxis to the CCR6 ligand, CCL20, by 
memory B cells
Using Phycoerythrin (PE) as an immunization antigen, the emergence and differentiation of 
PE-binding Bmem in vivo was quantified, as we have previously published (1, 20). We have 
previously shown (1) that PE-binding Bmem cells were defined as 
B220+PE+CD38+IgD−IgM−IgG1+ and naïve B cells as B220+IgM+CD38+IgD+IgG1−PE− 
(Supplementary Fig. 1A). Bmem and naïve B cell CCR6 mRNA and protein expression 
levels were determined in C57/BL6 mice immunized with PE 60 days previously. PE-
specific Bmem and naïve B cells were sorted with a purity over 95% and Ccr6 transcript 
levels were assessed. An increased level of Ccr6 transcript in PE-binding Bmem cells was 
observed when compared to that observed in naïve B cells (Fig. 1A). Flow cytofluorimetric 
analysis corroborated the heightened expression of CCR6 in Bmem by showing a higher 
percentage of Bmem expressed membrane CCR6 compared to naïve B cells (Fig. 1, B and 
C). Moreover, Bmem have a higher MFI in CCR6 expression when compared to naïve B 
cells (Fig. 1B). CCR6 expression was also analyzed in immature B cells (B220+IgMhiIgD−), 
mature B cells (B220+IgMintIgD+), pre B cells (B220+IgM−IgD−) and PCs 
(B220−CD138+IgD−) from BM (21). Mature B cells expressed similar levels of CCR6 
compared to naïve B cells and CCR6 expression is increased during the development of B 
cells (Fig. 1, D and E). Neither pre B cells nor PCs express this chemokine receptor (Fig. 1, 
D and E). These results together establish that Bmem cells express increased levels of CCR6 
mRNA and protein when compared to other B cell subsets, including PCs.
To evaluate whether CCR6 expression correlated with a heightened chemotactic response to 
CCR6 ligand, CCL20, in vitro migration assays were performed. Splenic B cell subsets were 
evaluated for their in vitro capability to migrate to different concentrations of a spectrum of 
chemokines. In vitro migration assays showed (Fig. 1, F and Supplementary Fig. 1B and C) 
that Bmem preferentially migrated in response to CCL20, in a dose-dependent manner when 
compared to naïve B cells. Bmem, like naïve B cells were also able to migrate to CXCL12 
and CXCL13. In addition, although naïve B cells also express CCR6, they did not migrate in 
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response to CCL20 (Supplementary Fig. 1B). These results established that Bmem, and not 
naïve B cells are able to migrate in response to CCL20.
CCR6 is dispensable for the primary humoral immune response
The expression of CCR6 by naïve B cells potentially implicated CCR6 as playing a role in 
the primary humoral immune response (Fig. 1B). To evaluate the role of CCR6 in a primary 
B cell response, the ability of CCR6-deficient mice to mount a T-dependent primary 
antibody response was evaluated. The lack of CCR6 did not disrupt splenic architecture in 
PE-immune mice and there was no difference in the GC structure (Fig. 2A) or frequency of 
GC B cells, as defined by B220+CD95+GL-7+CD38− B cells (Fig. 2, B, C, D and E) 14 days 
after immunization. Furthermore, there was no impact of CCR6-deficiency on anti–PE 
serum antibody titers or PE− specific IgG1+ BM-ASC at day 14 and 28 after immunization 
(Fig. 2F and 2G). These data show that CCR6 expression is not required for GC formation, 
the primary generation of antigen-specific ASC or enhanced serum antigen-specific 
antibody titers following primary immunization.
The heightened expression of CCR6 on Bmem suggested that it might play a role in the 
initial differentiation of Bmem during the primary response. To this end, CCR6 deficient and 
wild type mice were immunized with PE and after 4 months, the percentage of Bmem was 
analyzed by flow cytometry. Bmem were defined as B220+PE+CD38+IgD−IgM−IgG1+, as 
shown in Figure 2H, the frequency of Bmem cell in CCR6−/− mice and WT mice were 
indistinguishable between lymph nodes and spleen. These data established that CCR6 was 
dispensable for the differentiation of Bmem during the primary immune response.
Involvement of CCR6 in the recall response of Bmem
CCR6 is not involved in the development of the primary humoral immune response nor in 
the early differentiation of antigen-specific Bmem or ASC. Additional studies were designed 
to address the potential role of CCR6 in Bmem maintenance and recall responsiveness. As 
such, we analyzed the recall response in immune WT and CCR6-deficient mice. Immune 
CCR6-deficient and WT mice immunized 120 days previously were re-challenged with PE 
and 5 days later, the number of antibody secreting cells (ASCs) was quantified. The results 
show that there was a marked reduction in the number of PE-specific IgG1 ASCs in both 
spleen and BM of CCR6-deficient mice compare to WT mice (Fig. 3A and B). Also 
observed was a signficant reduction in the serum titers of anti-PE IgG1 (Fig. 3C). These 
observations indicated that the recall capacity of Bmem is impaired in the absence of CCR6.
To determine whether the defect in Bmem function in CCR6-deficient mice is intrinsic to the 
B cell lineage, mixed BM chimeras were produced. Reconstitution of irradiated wild-type 
hosts with a mixture of μMT BM with either CCR6-deficient or WT BM resulted in 
chimeras in which the B cell compartment was derived from CCR6-deficient or WT BM 
precursors and all other compartments were predominantly of a WT genotype (Fig. 3D). 
After the reconstitution of the hematopoietic compartment, the mice that were immunized 60 
days previously, were re-challenged with PE and 5 days later, the number of ASCs was 
analyzed by ELISPOT. The data showed that in both spleen and BM there were marked 
reductions in the number of ASCs in the chimeras where the B cells were derived from 
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CCR6-deficient BM compared to those chimeras where the B cells were derived from WT 
BM (Fig. 3E and F). These results show that B lineage-restricted expression of CCR6 is 
critical for Bmem cells to respond to a secondary challenge by antigen.
Involvement of CCR6 in the localization of Bmem
The immunohistological tracking of Bmem is challenging given the lack of a definitive set of 
easily usable markers to identify them in situ (22–24). Nonetheless, it was important to 
determine whether the deficiency of CCR6 resulted in the altered anatomic localization of 
Bmem. As such, the distribution of B cells in WT and CCR6-deficient mice was assessed. 
Tracking of Bmem was afforded by analysis using a mouse whereby Cre recombinase was 
inserted in the Cγ1 locus interbred with a mouse engineered with a conditional Rosa26-
EYFP allele (called here, RosaYFP) (25). In this strain, every post-GC B cell, including 
Bmem, expresses YFP. Flow cytofluorimetric analysis reveals that less than 1% of total B 
cells express YFP+ in the steady state (data not shown) (25). Subset analyses of the YFP+ 
cells in immune RosaYFP mice showed that the YFP+ population is compose of IgM/IgD+ 
and IgG+ activated B cells (Fig. 4A). Based on flow cytofluorimetric analysis, it was not 
evident that the YFP+ B cells that were IgM/IgD+ were Bmem, and as such were 
independently scored for their distribution. The splenic localization of YFP+, IgM−/IgD-, 
IgG1+ were quantified as a measure of Bmem distribution (Fig. 4B and F).
First, no difference were found in the percentage of activated or polyclonal Bmem cells in 
either the Cγ1-cre x RosaYFP x CCR6−/− and Cγ1-cre x RosaYFP mice (Fig. 4A and B), as 
expected from our analysis of the frequency of Bmem in CCR6−/− mice. Second, staining for 
YFP+ cells in WT mice revealed that the majority of the B220+, YFP+ cells were distributed 
widely outside of follicular areas. Note that double positive cells (B220+, YFP+) did not 
appear yellow because the YFP stain and the B220 stain were localized to the same cells but 
one stain was cytoplasmic (YFP) and the other localized to the plasma membrane 
compartment (B220). Third, polyclonal Bmem that were enumerated in RosaYFP mice by 
loss of IgD and IgM, were equally located outside the follicle/GC areas of the spleen, as 
predicted by prior studies showing the capacity of Bmem to localize to the marginal zone 
(Supplementary Fig. 2A) (24).
Finally, in the CCR6-deficient mice, where there was over a 6-fold increase of Bmem cells 
found in follicular areas compared to what was observed in WT mice (Fig. 4C, D, F). The 
results show that in the spleen of Cγ1-cre x RosaYFP x CCR6−/− mice, Bmem are re-
distributed to follicular/GC structures, which are associated with CD35 expression and PNA 
(Fig. G and H, supplemental Fig. 2E), whereas in control mice RosaYFP Bmem equally 
localize between perifollicular and marginal zone areas, co-localizing with MOMA 
expression (Supplementary Fig. 2A and B).
The striking increase in follicular restridistribution of vitually all YFP+ B cells in the 
CCR6−/− mice raised a number of additional questions. To determine whether an increase in 
GC numbers in the spleen of Cγ1-cre x RosaYFP x CCR6−/− in steady state could account 
for the redistribution of YFP+ cells, GC numbers were quantified. Although in CCR6−/− 
mice there is a tendency towards a higher percentage of GC B cells, this difference is not 
statistically significant in both percentage and absolute number (Fig. 4I and Supplementary 
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Fig. 2D and E), suggesting that the accumulation of activated B cells in the follicular areas is 
not due to an increase in GC B cells. Peri-follicular redistribution could also be the result of 
heightened expression of CXCR5 on Bmem relative to WT Bmem, and as such, the expression 
of CXCR5 was analyzed. CCR6−/− and WT mice express identical densities of CXCR5 
(Supplementary Fig. 3). This indicates that the selective migration of CCR6−/− Bmem is not 
due to heightened CXCR5 expression. Therefore, at this time, it is not clear why the loss of 
CCR6 results in the redistribution of B cells.
CCL20 is the ligand for CCR6 and as such, CCL20 gene expression in different splenic 
population of immune cells and whole spleen was evaluated in WT and CCR6−/− mice. 
qPCR for CCL20 gene indicated that CD4+ T cells were the major producers of CCL20 in 
the spleen (Fig. 4J). Our results also show that the CCL20 abundance in total spleen is 
similar that found in CD4+ T cells, indicating that the CCL20 signal is truly enriched in 
CD4+ T cells. Taken together, these results suggest that the lack of CCR6 expression on 
activated B cells prevents co-localization of Bmem with CCL20-expressing CD4+ T cell in 
the spleen, impacting on their ability to respond to antigen.
Discussion
Chemokine receptors play crucial role for the appropriate localization of Bmem in secondary 
lymphoid organs and impact on the ability of Bmem to mount an effective secondary immune 
response. To our knowledge, the findings presented here are the first to establish a critical 
role of CCR6 in Bmem function. The data shows that a high frequency of Bmem cells express 
CCR6 and have a heightened chemotactic response to CCL20 compared to naïve B cells. It 
is known that there is broad CCR6 expression across B cell subsets in the mouse and CCR6 
is expressed at higher levels transiently during cognate activation of B cells (26, 27). CCR6-
deficient mice have a faster GC response compared with littermate controls, resulting in an 
increase of low affinity antigen-specific plasmablasts (26). Interestingly though, like in this 
report, prior authors showed that there was heightened histological accumulation of 
activated B cells in the GC/follicle in the CCR6−/− mice. In studying the primary response to 
PE, we did not observe any difference in the primary immune response, with regard to GC 
formation, BM-PCs or antibody titers when compared to control mice. Our findings show 
that Bmem retain high expression of CCR6 during the immunization period compared with 
that constitutively expressed on naïve B cells. A significant impact of B cell intrinsic CCR6-
deficiency was a loss in the secondary recall response of Bmem. Because chemokines are 
important in the anatomic migration and localization of cells within secondary lymphoid 
organs (28), it is proposed that the absence of CCR6 expression impacts on the localization 
of established Bmem to receive the suitable signals to become PCs. Alternatively, CCR6 may 
play a role in PC survival, however, this unlikely since our own data (Figure 1E) and 
published studies report that PCs do not express CCR6 (29).
Loss of CCR6 appears to dramatically alter the histological distribution of activated B cells. 
Attempts to detect Bmem in vivo in order to identify their location and migratory patterns 
have been met with limited success (22–24). It has been reported that there is preferential 
localization of Bmem adjacent to contracted GCs in the spleen, which may be chemokine 
dependent, and which is different to the behavior of primary B cells that are responding to 
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antigen (22). Furthermore, it has been argued that Bmem cells localized in marginal zone 
area are IgM-Bmem cells (22–24). In our model, using YFP expression under Cγ1-Cre 
promoter to help identify Bmem, it was observed that polyclonal Bmem cells are widely 
distributed across the marginal zone and perifollicular area, suggesting that it is not the 
exclusive location for antigen experienced IgM+ B cells as was proposed previously (22–
24). Most importantly, we observed an accumulation of Bmem in the follicular areas in the 
absence of CCR6 expression. Why this redistribution of Bmem impairs their ability to mount 
a recall response to the cognate antigen is currently under investigation.
qPCR analysis in immune mice revealed that CCL20 is expressed on CD4 T cells in the 
spleen, and provides a reasonable basis for suggesting that antigen-primed CD4+ T cell 
produce CCL20, and instruct the chemotaxis of CCR6-bearing Bmem to facilitate cognate 
interactions in the secondary humoral response. CCL20 is expressed at low levels in splenic 
CD4+ T cells at steady state compared with Peyer’s patches. However, it is significantly 
induced by pro-inflammatory signals via TLRs agonists or TNFα (30). CCL20 is not the 
only ligand for CCR6; β-defensins and other non-chemokine proteins can also be ligands for 
CCR6. However, their affinity is much lower compared to CCL20 (31). CCR6 expression 
and the chemotactic response to CCL20 on Bmem cells is consistent with CCR6 being an 
important molecule in the systemic migration Bmem to mucosal and effector sites (18, 19), 
an event perhaps critical in the lifespan of Bmem. Loss of CCR6 disorganized the co-
localization of CCL20 producing T cells and Bmem which likely contributed to the impaired 
recall responses of Bmem to their cognate antigen.
In conclusion, CCR6 is highly expressed on Bmem, and has an important role in the Bmem 
function and localization in secondary lymphoid organs. Due to the profound role of CCR6 
in the regulation of secondary humoral immune responses, this chemokine is an attractive 
target in diseases where the recall responses of Bmem contribute significantly to disease 
pathogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. CCR6 expression on memory B cells and their chemokine response profile
(A) PE-specific Bmem cells (B220+ CD38+ PE+ IgG1+ and IgM/IgD/CD4/CD8-) and naïve 
B cells (NF B cells) (B220+ CD38+ CD23+ IgG1- and IgM/IgD+) were sorted and mRNA 
expression levels of CCR6 were analyzed. (B) Flow cytometry analysis of CCR6 expression 
on naïve B cells (left panel) and Bmem cells (right panel). Numbers indicates percentage of 
CCR6 positive cells. (C) Quantification for CCR6 expression in naïve and Bmem cells by 
flow cytometry in B is shown. (D) Flow cytometry analysis of CCR6 expression on 
immature B cells (B220+IgMhiIgD−), mature B cells (B220+IgMintIgD+), pre B cells 
(B220+IgM−IgD−) and PCs (B220−CD138+IgD−) from bone marrow. (E) Percentage of 
CCR6 positive cells of each subset in D and NF B cells is shown. All data are representative 
of at least three independent experiments with at least 3 mice/group. (F) Quantification of 
chemokine profile response at 250 ng/mL of Bmem cells from 3 independent experiments, 
each sample in duplicate. *p<0.01, ** p<0.001.
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Fig. 2. CCR6 expression on B cells does not affect the primary humoral response or memory B 
cell development
(A) CCR6KO (right panel) or wt (left panel) mice were immunized with 10 ug of PE 
adsorbed in alum, after 7 days, the spleen were frozen and stained with PNA-FITC (Green), 
B220-alexafluor647 (Blue) and CD4-biotin plus streptoavidin-alexafluor455 (Red) for 
germinal center analysis. The original magnification is 10x. A representative image of two 
independent experiments with 3 mice/group. Bar represents 80 μm. (B) Flow cytometry 
analysis of GC B cells (B220+CD38−CD95+GL-7+) in wt or CCR6KO mice, non-
immunized (NI; bottom panels) or immunized (top panels) with PE in alum 14 days before 
of the analysis. (C) Histogram of PE binding in GC B cells gated in B is shown. (D) 
Percentage of GC B cells of total B220+ cells at day 14 after immunization is shown. (E) 
Quantification of PE specific GC B cells of total B220+ cells is shown. One representative 
test from two independent experiments with at least 3 mice/group. (F) CCR6KO or wild-
type mice were immunized with 10 ug of PE adsorbed in alum, non-immunized mice (day 0) 
and 14 and 28 days after immunization, the serums were collected to analyze the production 
of anti-PE IgG1 titers by ELISA. (G) BMs were collected at the same time point than F to 
analyze number of PE+ IgG1+ BM-ASC by ELISPOT. Quantification from two independent 
experiments with at least 3 mice/group. (H) CCR6KO or wt mice were immunized with 10 
ug of PE in alum. 120 days after, the percentage of PE specific Bmem cells 
(PE+IgG1+B220+CD38+IgM/IgD−) were evaluated in mesenteric (MLN), peripherical 
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lymph (PLN) node and spleen by flow cytometry. The graph shows the quantification of two 
independent experiments with 3 mice/group.
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Fig. 3. The secondary humoral response is defective in CCR6−/− mice
CCR6KO and wt mice were immunized with 10 ug of PE in alum, after 120 the mice were 
re-immunized with 10 ug of soluble antigen PE and 5 days later, the number of anti-PE+ 
IgG1+ PC from spleen (A) and bone marrow (B) were analyzed by ELISPOT. (C) 
Quantification of anti-PE IgG1 levels after recall response in serum from (A and B). 
Quantification of two independent experiments with 4 mice per group. **p<0.001. (D) 
Representative density plot of CCR6 expression on B cells after the generation of bone 
marrow chimeras from CCR6KO (right panel) or wild type (left panel) donor-derived. 
Number of donor-derived of PE-specific IgG1 PC in spleen (E) and bone marrow (F) 
analyzed by ELISPOT in chimeric CCR6KO and wt mice immunized with 10 ug of PE in 
alum and challenged 60 days after with 10 μg of soluble PE. *p<0.01.
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Fig. 4. CCR6 affects the localization of Bmem cells
(A) Quantification of splenic YFP+ B cell composition from Cγ1-cre x ROSAYFP x 
CCR6−/− or Cγ1-cre x ROSAYFP is shown. (B) Percentage of polyclonal Bmem 
(B220+IgG1/YFP+CD38+Dump−CD80+) from spleens of Cγ1-cre x ROSAYFP x CCR6−/− 
or Cγ1-cre x ROSAYFP is shown. (C, E, G) Histology of YFP expression (green) co-
localizing with B220 (C), IgM/IgD (E) and CD35 (G) in red. (D, F, H) Quantification of 
YFP+B220+ (D), YFP+IgM/IgD− (F), YFP+CD35+ (H) on histological section of the spleen 
in the marginal zone and perifollicular area of Cγ1-cre x ROSAYFP x CCR6−/− or Cγ1-cre 
x ROSAYFP mice. (I) Percentage of GC B cells (CD95+GL-7+) of total YFP+ B220+ cells 
by flow cytometry is shown. (J) CCL20 gene expression on splenic CD4, CD8 T cells, B 
cells and monocytes, in addition to whole spleen and Peyer’s patch tissue. Graph represents 
2 independent experiments with 4 mice per group.
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